肝细胞癌患者经导管化疗栓塞治疗结局相关独立危险因素的单中心回顾分析-东南大学学报医学版

肝细胞癌患者经导管化疗栓塞治疗结局相关独立危险因素的单中心回顾分析

单位：东南大学附属中大医院放射科, 江苏南京 210009

分类号：R735.7

出版年·卷·期（页码）：2014·33·第六期（734-741）

摘要：

目的: 探讨肝细胞癌(HCC)患者经导管化疗栓塞(TACE)治疗后复发和生存相关的独立危险因素.方法: 收集我院因HCC而接受TACE治疗的135例患者的临床资料,进行回顾性分析,与肿瘤复发和患者生存相关的危险因素采用Cox回归风险模型进行研究.结果: 135例HCC患者中位生存时间为25个月(95%CI为18.816 8~32.757 5).单因素和多因素Cox回归分析显示:Child P分级(校正RR=1.379,95%CI为1.033~1.841,P=0.029)、患有糖尿病和高血压(校正RR=1.621,95%CI为1.199~2.192,P=0.002)是患者生存的独立危险因素.另外,糖尿病和高血压的合并症(校正RR=1.775,95%CI为1.233~2.554,P=0.002)是肿瘤复发的唯一危险因素.结论: 患有糖尿病和高血压是TACE治疗HCC患者生存和肿瘤复发的独立危险因素

Objective: To investigate the potential independent risk factors associated with recurrence of hepatocellular carcinoma(HCC) and patients survival after transcatheter arterial chemoembolization(TACE). Methods: The data of patients with hepatocellular carcinoma who underwent transcatheter arterial chemoembolization in our hospital,were retrospectively analyzed. The independent risk factors associated with patients survival and recurrence of HCC were analyzed using the Cox proportional hazard model.A P-value of less than 0.05 was considered to indicate a significant difference. Results: This study included 135 patients.The median survival time was 25 months(95%CI:18.8168-32.7575). Univariate and multivariate Cox regression analysis revealed the independent factors associated with a poor survival:Child P class (adjusted RR=1.379,95%CI:1.033-1.841,P=0.029) and the association of DM and HT(adjusted RR=1.621,95%CI:1.199-2.192,P=0.002).The association of DM and HT(adjusted RR=1.775,95%CI:1.233-2.554,P=0.002) was the sole independent risk factor for tumor recurrence. Conclusion: The association of diabetes mellitus and hypertension is an independent risk factor for both survival and tumor recurrence.

参考文献：

[1] JEMAL A,BRAY F,CENTER-MELISSA M,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2] NICOLAE B,GUSTAV A,IRINEL O,et al.CT and MR imaging of hepatocellular carcinoma[J].J Gastrointestin Liver Dis,2011,20(2):181-189.
[3] GU Y K,LUO R G,HUANG J H,et al.Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture[J].World J Gastroenterol,2010,16(45):5766-5772.
[4] OZKAVUKCU E,HALILOGLU N,ERDEN A.Post-treatment MRI findings of hepatocellular carcinoma[J].Diagn Interv Radiol,2009,15(2):111-120.
[5] DAVIDE I,PIETRO A B,LAURA R,et al.Hepatocellular carcinoma treated with transarterial chemoembolization:dynamic perfusion-CT in the assessment of residual tumor[J].World J Gastroenterol,2010,16(47):5993-6000.
[6] ANTOINE B F,REAL L,PIERRE P,et al.Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation:a Retrospective Clinical Study[J].Int J Hepatol,2011,2011:974514.
[7] TAKANORI H,MAYASUKI K,KAORU T,et al.Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy[J].World J Gastroenterol,2013,19(2):249-257.
[8] WU K T,WANG C C,LU L G,et al.Hepatocellular carcinoma:clinical study of long-term survival and choice of treatment modalities[J].World J Gastroenterol,2013,19(23):3649-3657.
[9] EHUD G,FRANZ H M,VALENTINA B,et al.Is there an association between hypertension and cancer mortality？[J].Am J Med,2002,112(6):479-486.
[10] BAE S Y,CHOI M S,GWAK G Y,et al.Comparison of usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B endemic area[J].Clin Mol Hepatol,2012,18(2):185-194.
[11] CABIBBO G,GENCO C,di MARCO V,et al.Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation[J].Aliment Pharmacol Ther,2011,34(2):196-204.
[12] IRENE B,RODOLFO S,ELENA B,et al.Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment:a prospective cohort study[J].Eur J Radiol,2012,81(6):1173-1178.
[13] SUK K J,YUN K C,YONG S A,et al.Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization:focusing on superselective chemoembolization[J].Korean J Radiol,2008,9(6):534-540.
[14] KENICHI T,YOSHIHISA M,TETSUO M,et al.Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system:analysis of factors affecting local recurrence and survival rates[J].Am J Roentgenol,2001,176(3):681-688.
[15] EUN S J,JI H K,EILEEN L Y,et al.Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J].J Hepatol,2013,58(6):1181-1187.
[16] SHASHI B P,SHIVANAND G,VISHNUBHATLA S,et al.Transarterial chemoem bolization(TACE) in patients with unresectable Hepatocellular carcinoma:experience from a tertiary care centre in India[J].Indian J Radiol Imaging,2011,21(2):113-120.
[17] SAWHNEY S,MONTANO-LOZA A J,SALAT P,et al.Transarterial chemoem bolization in patients with hepatocellular carcinoma:predictors of survival[J].Can J Gastroenterol,2011,25(8):426-432.
[18] XU L T,ZHOU Z H,LIN J H,et al.Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma[J].Eur J Surg Oncol,2011,37(3):245-251.
[19] WANG W M,XU Y,YANG X R,et al.Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments:a meta-analysis[J].Hepatobiliary Pancreat Dis Int,2011,10(4):346-355.
[20] ZHANG J W,FENG X Y,LIU H Q,et al.CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma after TACE[J].World J Gastroenterol,2010,16(16):2038-2045.
[21] SHI M,CHEN J A,LIN X J,et al.Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China[J].World J Gastroenterol,2010,16(2):264-269.
[22] RENUMATHLY D,DAVID A K,CHARLES A S,et al.Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads:a preliminary study[J].HPB(Oxford),2010,12(3):174-180.
[23] MARTY T S,SIDNEY H,KRISTY K,et al.Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma[J].J Vasc Interv Radiol,2013,24(5):647-654.
[24] IDILMAN I,PEYNIRCIOQLU B,CIL B E,et al.Transarterial chemoembolization for treatment of hepatocellular carcinoma:a single center experience[J].Turk J Gastroenterol,2013,24(2):141-147.
[25] GREGORY C C,SAMAN S,RANDEEP K,et al.Diabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma[J].BMC Gastroenterol,2013,14(13):9.
[26] STRICKLER H D,WYLIE-ROSETT J,ROHAN T,et al.The relation of type 2 diabetes and cancer[J].Diabetes Technol Ther,2001,3(2):263-274.
[27] YANG W S,PUTHIERY V A,FREDDIE B,et al.The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis:a Meta-analysis of prospective cohort studies[J].PLoS One,2011,6(12):e27326.
[28] BROOKES M J,COOPER B T.Hypertension and fatty liver:guilty by association？[J].J Hum Hypertens,2007,21(4):264-270.
[29] ALISA S M,ELAZER R,EDELMA N.Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability[J].J Biol Chem,2007,282:14635-14644.
[30] DAVID R C,LAURA A M,YAN L,et al.Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress[J].Growth Horm IGF Res,2007,17(4):265-270.
[31] YASHWANTH R,LAURA A M,YAN L,et al.Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells[J].J Biol Chem,2008,283(24):16320-1631.
[32] KER J A.Hypertension and diabetes:bad companions[J].SA Fam Pract,2004,46(9):14.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录